投资银行Leerink Partners宣布,首次将生物制药公司Terns Pharmaceuticals, Inc.纳入研究覆盖范围,并给予其“跑赢大盘”的评级。分析师为该股设定了58美元的目标股价。
投资银行Leerink Partners宣布,首次将生物制药公司Terns Pharmaceuticals, Inc.纳入研究覆盖范围,并给予其“跑赢大盘”的评级。分析师为该股设定了58美元的目标股价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.